# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Canaccord Genuity analyst Richard Close maintains Progyny (NASDAQ:PGNY) with a Buy and lowers the price target from $46 to $37.
Progyny reported first-quarter sales of $278.1 million, slightly below expectations due to increased clients and covered lives....
BTIG analyst David Larsen maintains Progyny (NASDAQ:PGNY) with a Buy and lowers the price target from $50 to $41.
Keybanc analyst Scott Schoenhaus downgrades Progyny (NASDAQ:PGNY) from Overweight to Sector Weight.